Ren Tianyi, Wang Huan, Wu Ruihong, Niu Junqi
Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Jilin Province Key Laboratory of Infectious Disease, Laboratory of Molecular Virology, Changchun 130021, China.
Gastroenterol Res Pract. 2017;2017:7089702. doi: 10.1155/2017/7089702. Epub 2017 Jul 31.
We want to investigate whether a novel noninvasive marker is suitable for Chinese CHB patients.
A total of 160 treatment-naïve CHB patients who underwent liver biopsy were enrolled in our study, and we assessed the diagnostic accuracies of GPR, aspartate transaminase-to-platelet ratio index (APRI), and the fibrosis index based on 4 factors (FIB-4) in them.
Of these 160 CHB patients, the numbers of F0, F1, F2, F3, and F4 are 34 (21.3%), 62 (38.8%), 18 (11.3%), 24 (15%), and 22 (13.8%), respectively. The area under the receiver operating characteristic curves (AUROC) of GPR for fibrosis (0.77 versus 0.70, = 0.03), significant fibrosis (0.70 versus 0.63, = 0.02), and extensive fibrosis (0.71 versus 0.64, = 0.02) were significantly higher than those of APRI. The AUROCs of GPR and Fib-4 for fibrosis (0.77 versus 0.75, = 0.14), significant fibrosis (0.70 versus 0.70, = 0.22), extensive fibrosis (0.71 versus 0.68, = 0.13), and cirrhosis (0.64 versus 0.67, = 0.24) were comparable.
The GPR can be a routine laboratory marker to stage liver fibrosis in patients with CHB in China.
我们想要研究一种新型非侵入性标志物是否适用于中国慢性乙型肝炎（CHB）患者。
本研究纳入了160例初治CHB患者，这些患者均接受了肝活检，我们评估了其中GPR、天冬氨酸转氨酶与血小板比值指数（APRI）以及基于4项因子的纤维化指数（FIB-4）的诊断准确性。
在这160例CHB患者中，F0、F1、F2、F3和F4期的患者数量分别为34例（21.3%）、62例（38.8%）、18例（11.3%）、24例（15%）和22例（13.8%）。GPR用于肝纤维化（0.77对0.70，P = 0.03）、显著肝纤维化（0.70对0.63，P = 0.02）和广泛肝纤维化（0.71对0.64，P = 0.02）的受试者工作特征曲线下面积（AUROC）显著高于APRI。GPR和FIB-4用于肝纤维化（0.77对0.75，P = 0.14）、显著肝纤维化（0.70对0.70，P = 0.22）、广泛肝纤维化（0.71对0.68，P = 0.13）和肝硬化（关于肝硬化的翻译存疑，原文cirrhosis前面有个and，这里单独翻译不好处理，可根据上下文调整为“以及肝硬化（0.64对0.67，P = 0.24）”）的AUROC相当。
在中国，GPR可作为CHB患者肝纤维化分期的常规实验室标志物。
